Genetic abnormalities as targets for molecular therapies in myelodysplastic syndromes.
about
Tyrosine kinase inhibitors induced thyroid dysfunction: a review of its incidence, pathophysiology, clinical relevance, and treatmentClinical implications of the quantitative detection of ID4 gene methylation in myelodysplastic syndrome.Eight-channel iTRAQ enables comparison of the activity of six leukemogenic tyrosine kinases.
P2860
Genetic abnormalities as targets for molecular therapies in myelodysplastic syndromes.
description
2006 nî lūn-bûn
@nan
2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Genetic abnormalities as targets for molecular therapies in myelodysplastic syndromes.
@ast
Genetic abnormalities as targets for molecular therapies in myelodysplastic syndromes.
@en
Genetic abnormalities as targets for molecular therapies in myelodysplastic syndromes.
@nl
type
label
Genetic abnormalities as targets for molecular therapies in myelodysplastic syndromes.
@ast
Genetic abnormalities as targets for molecular therapies in myelodysplastic syndromes.
@en
Genetic abnormalities as targets for molecular therapies in myelodysplastic syndromes.
@nl
prefLabel
Genetic abnormalities as targets for molecular therapies in myelodysplastic syndromes.
@ast
Genetic abnormalities as targets for molecular therapies in myelodysplastic syndromes.
@en
Genetic abnormalities as targets for molecular therapies in myelodysplastic syndromes.
@nl
P2093
P2860
P356
P1476
Genetic abnormalities as targets for molecular therapies in myelodysplastic syndromes.
@en
P2093
Daniela Cilloni
Emanuela Messa
Enrico Bracco
Francesca Messa
Ilaria Defilippi
Paolo Nicoli
Renata Catalano
Sonia Carturan
Valentina Rosso
P2860
P304
P356
10.1196/ANNALS.1386.030
P407
P577
2006-11-01T00:00:00Z